Randomized trial investigates RSPO2's role in suppressing breast cancer progression by inducing ferroptosis, highlighting potential therapeutic target.
Key Points
This research aims to uncover how RSPO2 influences breast cancer progression through ferroptosis mechanisms.
Evaluated RSPO2 expression in primary breast cancer specimens and cell lines (MCF-7, MDA-MB-231).
Performed in vitro functional assays (proliferation, migration, invasion) and in vivo tumor growth assessment using a xenograft model.
Utilized RNA sequencing, immunoprecipitation, and mRNA stability assays to investigate the molecular mechanisms.
RSPO2 was downregulated in malignant breast cancer tissues, while its restoration suppressed cell proliferation, migration, and invasion (p<0.01).
RSPO2 overexpression led to reduced PTBP1 levels, resulting in decreased FSP1 mRNA stability and increased ferroptosis markers (ROS accumulation, GSH depletion).
FSP1 overexpression reversed the inhibitory effects of RSPO2 on cell proliferation and invasion, indicating its role in the RSPO2 signaling axis.